Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

US House Passes Legislation to Enable Venture Backed Small Business to Qualify

Related Content

The Court of Appeals for the Federal Circuit’s In Re Xencor Decision: Jepson Claims Require Written Description for Their Preambles

FDA Accepts BLA for Alvotech and Dr. Reddy’s Denosumab Biosimilars

Celltrion Launches STEQEYMA® (ustekinumab-stba) in the United States

FDA Approves Celltrion’s OMLYCLO® (omalizumab-igec)

Federal Circuit Affirms Denial of Injunction Against Amgen in Aflibercept BPCIA Litigation

Biosimilars Webinar: Prosecution and Litigation Trends and Takeaways from BPCIA Litigation

Boston Forum: Merger Control & Competition in Life Sciences

FDA Accepts BLA for Amneal’s Denosumab Biosimilars

Boston Forum: Merger Control & Competition in Life Sciences

Goodwin’s Annual Healthcare & Life Sciences Summit

Goodwin Advised Harbour BioMed in $175 Million Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

Leading the Charge in Life Sciences Litigation, Goodwin is Shortlisted For Three Managing IP Awards

Goodwin Advises Dren Bio in Acquisition of Bispecific Myeloid Cell Engager by Sanofi

Maxion Therapeutics Raises $72 million in Series A Round

Goodwin Advises Isomorphic Labs on Collaboration Expansion with Novartis

Gubra Enters $2.225 Billion License Agreement with AbbVie to Develop an Amylin Analog for the Treatment of Obesity

Life Sciences

Technology